MedTrace Logo

Berberine and Altered Fasting Glucose

NCT05031715 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-03-03

No results posted yet for this study

Summary

The aim of the study was to evaluate the effectiveness of a food supplement, berberine phytosome, which contributes to the control of blood sugar and the improvement of insulin resistance.

Conditions

  • Glucose Metabolism Disorders

Interventions

DIETARY_SUPPLEMENT

Berberine Phytosome

2 tablets of 550 mg per day (1 before lunch and 1 before dinner)

Sponsors & Collaborators

  • Azienda di Servizi alla Persona di Pavia

    lead OTHER

Principal Investigators

  • Mariangela Rondanelli · Fondazione Casemiro Mondino

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-02
Primary Completion
2020-05-28
Completion
2022-07-25

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05031715 on ClinicalTrials.gov